BRCA2 and ovarian carcinoma: A genome-wide short hairpin RNA (shRNA) screen performed by Guillemente et al. (71) has identified the chromatin remodeling factor CHD4 to promote cisplatin resistance in BRCA2-mutated ovarian cancer cell line PEO-1 upon its downregulation.